[HTML][HTML] Patient-reported outcomes with direct-acting antiviral treatment for hepatitis C in West and Central Africa (TAC ANRS 12311 trial)
F Marcellin, A Mourad, M Lemoine, C Kouanfack… - JHEP Reports, 2023 - Elsevier
Background & Aims Patient-reported outcomes (PROs) are poorly documented for patients
with chronic hepatitis C on direct-acting antiviral (DAA) treatment in low-to-middle-income …
with chronic hepatitis C on direct-acting antiviral (DAA) treatment in low-to-middle-income …
Impact of IL28B gene polymorphism on efficacy and safety of direct acting antivirals in hepatitis C Egyptian patients
AHIM Ebid, OA Ahmed, SH Agwa… - International Journal of …, 2020 - Springer
Background Hepatitis C virus infection is one of the major causes of liver cirrhosis and
hepatocellular carcinoma worldwide. IL28B gene polymorphism has a direct relation to the …
hepatocellular carcinoma worldwide. IL28B gene polymorphism has a direct relation to the …
Evaluation of the safety and resistance associated variants of sofosbuvir/daclatasvir among egyptian patients with hepatitis C virus: a prospective study
A Ramadan, H Karam, SS Abdel-Monem… - Bulletin of …, 2022 - journals.ekb.eg
Background: Hepatitis C virus (HCV) is a major health problem. Current treatment by direct-
acting antivirals achieved high sustained virological response (SVR). However, drug …
acting antivirals achieved high sustained virological response (SVR). However, drug …
[HTML][HTML] Micro-elimination of hepatitis C in patients with chronic kidney disease: an Egyptian single-center study
T George Michael, CA Anwar, OA Ahmed… - The Egyptian Journal of …, 2022 - Springer
Background and aims Micro-elimination of hepatitis C in renal patients is crucial. This study
aims to assess the efficacy and safety of directly acting antivirals in chronic kidney disease …
aims to assess the efficacy and safety of directly acting antivirals in chronic kidney disease …
[HTML][HTML] Assessment of efficacy and safety of two Egyptian protocols for treatment-experienced HCV patients: an observational study
RS Hagag, MM Fakhry, OA Ahmed… - The Egyptian Journal of …, 2022 - Springer
Background The devastating adverse effects of interferon (IFN) for the treatment of hepatitis
C virus (HCV) lead to the emerging of direct acting antiviral agents (DAAs). This …
C virus (HCV) lead to the emerging of direct acting antiviral agents (DAAs). This …